- Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases
-
One effective means to achieve inhibitor specificity for RAF kinases, an important family of cancer drug targets, has been to target the monomeric inactive state conformation of the kinase domain, which, unlike most other kinases, can accommodate sulfonamide-containing drugs such as vemurafenib and dabrafenib because of the presence of a unique pocket specific to inactive RAF kinases. We previously reported an alternate strategy whereby rigidification of a nonselective pyrazolo[3,4-d]pyrimidine-based inhibitor through ring closure afforded moderate but appreciable increases in selectivity for RAF kinases. Here, we show that a further application of the rigidification strategy to a different pyrazolopyrimidine-based scaffold dramatically improved selectivity for RAF kinases. Crystal structure analysis confirmed our inhibitor design hypothesis revealing that 2l engages an active-like state conformation of BRAF normally associated with poorly discriminating inhibitors. When screened against a panel of distinct cancer cell lines, the optimized inhibitor 2l primarily inhibited the proliferation of the expected BRAFV600E-harboring cell lines consistent with its kinome selectivity profile. These results suggest that rigidification could be a general and powerful strategy for enhancing inhibitor selectivity against protein kinases, which may open up therapeutic opportunities not afforded by other approaches.
- Assadieskandar, Amir,Yu, Caiqun,Maisonneuve, Pierre,Kurinov, Igor,Sicheri, Frank,Zhang, Chao
-
supporting information
p. 1074 - 1080
(2019/06/24)
-
- ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
-
A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.
- -
-
Paragraph 0203; 0204; 0205; 0206
(2017/06/12)
-
- BRIDGED BICYCLIC KALLIKREIN INHIBITORS
-
Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.
- -
-
Page/Page column 271; 272
(2016/12/26)
-
- A practical and mild chlorination of fused heterocyclic N-oxides
-
Fused azine N-oxides were selectively chlorinated at C2 in moderate to excellent yields, employing Vilsmeier reagent as both the activating agent and the nucleophilic chloride source. Remarkable features of the method include simple operation, mild reaction conditions, a wide substrate scope, and the use of only stoichiometric amount of POCl3. The potential extension of this method to a one-pot oxidation/chlorination sequence that obviates the need for isolation of the N-oxide intermediates is also validated.
- Wang, Dong,Jia, Hailing,Wang, Wuchang,Wang, Zhe
-
supporting information
p. 7130 - 7132
(2015/02/02)
-
- NOVEL BICYCLIC COMPOUND OR SALT THEREOF
-
Provided is a novel bicyclic compound which has an HSP90 inhibitory effect and a carcinostatic effect. Also provided is a pharmaceutical agent which is based on the HSP90 inhibitory effect and is useful in the prevention and/or treatment of a disease involving HSP90, particularly, cancer. The present invention provides a compound represented by the following general formula (I) or a salt thereof wherein at least one of X1, X2, X3, and X4 represents N or N-oxide and the rest thereof are the same or different and each represent C—R2; any one or two of Y1, Y2, Y3, and Y4 represent C—R4 and the rest thereof are the same or different and each represent CH or N;R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O;R2 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.;R3 represents a hydrogen atom, —CO—R5 etc.;R4 represents a hydrogen atom, —CO—R6, —N(R7)(R8) etc.;R5 represents a hydroxyl group, an amino group etc.;R6 represents a hydroxyl group etc.;R7 and R8 are the same or different and each represent a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; and R9 represents an optionally substituted cycloalkyl group having 3 to 7 carbon atoms etc.
- -
-
Paragraph 0180
(2013/11/19)
-
- BIS-ARYL AMIDE DERIVATIVES AND METHODS OF USE
-
Selected compounds are effective for prophylaxis and treatment of diseases, such as c Met mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
- -
-
Page/Page column 59-60
(2008/12/07)
-
- BIS-ARYL KINASE INHIBITORS AND METHOD
-
Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
- -
-
Page/Page column 33; 47
(2010/11/25)
-
- SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS
-
A compound of Formula (I) wherein: One of R1 and R2 is H and the other represents - NHCONHR4 wherein R4 represents a phenyl or naphthyl group (which may be optionally substituted by one or more substituents independently selected from -C1-6 alkyl, -C1-6 haloalkyl, - CH2CH2CH2-, halogen, C1-6 alkoxy, C1-6 haloalkoxy, OH, NO2), C3-7 cycloalkyl or R4 together with the NH to which it is bonded forms a morpholino group and R3 is H or NHR5 wherein R5 is H, -quinolinyl or -isoquinolinyl, -(CONH)p phenyl (wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C1-6 alkyl, -C1-6 haloalkyl, -morpholino, -SO2NH2, benzothiazole (substituted by methyl)) or a salt, solvate, or physiologically functional derivative thereof.
- -
-
Page/Page column 29
(2008/06/13)
-
- 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5
-
A compound of Formula (I) wherein R1 represents a phenyl or napthyl group (each of which is optionally substituted by one or more substituents independently selected from -OH, -C1-6alkyl, C1-6haloalkyl, -OCH2OCH3, -C1-6alkoxy, -halogen,), or a mono or bicyclic heteroaryl group comprising 1, 2 or 3 nitrogen atoms, optionally substituted by -C1-6alkoxy, -C1-6alkyl, C1-6haloalkyl or =0; R2 represents H, benzoimidazolyl, benzothiazolyl, isoquinolinyl, or quinolinyl group or phenyl (said phenyl being optionally substituted by -NR3R4, -C1-4alkoxy, -C1-6alkyl, -CONR3R4, -SO2NR3R4, -NHCONR3R4, -NHCOC1-6alkyl, -C1-6haloalkyl, -OCH2O-, -phenoxy (wherein the phenyl moiety is optionally substituted by NH2 ), -C1-3alkyl, -C1-3alkoxy, -CF3, -5 membered heteroaryl group comprising one or two nitrogen atoms). R3 and R4 are independently selected from H, -C1-6alkyl, -C1-3alkylNR5R6; R5 and R6 are independently H or C1-3alkyl; or a salt, solvate, or physiologically functional derivative thereof.
- -
-
Page/Page column 28-29
(2008/06/13)
-
- N-coating heterocyclic compounds
-
A compound of the formula (I): wherein A is a hydrogen atom, an optionally substituted, unsaturated, N-containing heterocyclic group or a group of the formula (a): wherein R is an optionally substituted aryl group or an optionally substituted heterocyclic group; M is —(CH2)n-, —(CH2)n-O—(CH2)m-or —(CH2)n-NH—(CH2)m-, wherein n and m are independently 0, 1 or 2; Q is an optionally substituted cycloalkylene group, an optionally substituted arylene group or an optionally substituted divalent heterocyclic group; and the moiety of the formula (b): is an optionally substituted, unsaturated, mono-, di-, tri- or tetra-cyclic, N-containing heterocyclic group which may contain additional hetero atom(s) selected from the group consisting of nitrogen, oxygen and sulfur atoms as the ring member(s), its prodrug or a pharmaceutically acceptable salt thereof.
- -
-
-